Kidney cancer Cancer Malignant neoplasm of kidney
Conditions
Interventions
After consent, and eligibility is confirmed, all participants will attend for the study 99mTc Sestamibi SPECT/CT scan (MIBI-kidney). This is likely to take place within 2 weeks of providing consent. T
Sponsors
University College London
Eligibility
Sex/Gender
All
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: 1. Age >18 years, and 2cm identified on cross sectional imaging (CT or MRI) of unknown histological diagnosis 4. Patients undergoing tumour biopsy or surgery as part of routine care 5. Willing and able to provide informed consent.
Exclusion criteria
Exclusion criteria: 1. Females who are pregnant, planning pregnancy or breastfeeding 2. Concurrent and/or recent involvement in other research that is likely to interfere with the intervention within 3 months of study enrolment 3. Multiple comorbidities which would make trial participation difficult (e.g. burden of an additional hospital visit). 4. Allergy to 99mTc Sestamibi
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Recruitment rate will be recorded as the number of eligible participants who consent to participate in the study after 15 months of recruitment. 2. Attrition rate will be recorded as the number of participants that enroll in the study but do not complete activities outlined in the protocol. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Qualitative data will be obtained from semi-structured video-interviews after the intervention to assess barriers and enablers of trial set-up, recruitment and delivery. 2. Exploratory health economic analysis will be informed by quality-of-life assessment at baseline and 24 hours after MIBI-kidney using the validated EQ-5D-5L instrument. 3. Costs incurred by MIBI-kidney, and other stages of the diagnostic pathway will be collected from NHS reference costs at the end of the study to inform design of a future health economic analysis | — |
Countries
England, United Kingdom
Outcome results
None listed